Advisors Preferred LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Advisors Preferred LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 20,358 shares of the biopharmaceutical company’s stock, valued at approximately $1,526,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HALO. Empowered Funds LLC acquired a new position in Halozyme Therapeutics during the first quarter worth about $755,000. Acadian Asset Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at approximately $195,000. First Citizens Bank & Trust Co. purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $436,000. Asset Management One Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $98,000. Finally, AlphaQuest LLC grew its holdings in shares of Halozyme Therapeutics by 2,933.1% in the 2nd quarter. AlphaQuest LLC now owns 5,308 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 5,133 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Benchmark lifted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday. Finally, Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $78.56.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the transaction, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the completion of the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $53,947,690.28. The trade was a 2.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 49,398 shares of company stock worth $3,650,592 in the last three months. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Down 1.5%

HALO opened at $70.98 on Friday. The firm has a market cap of $8.38 billion, a P/E ratio of 28.51, a PEG ratio of 0.29 and a beta of 0.97. The business’s fifty day simple moving average is $72.14 and its 200 day simple moving average is $70.43. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company has a quick ratio of 1.37, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same period in the previous year, the firm posted $1.26 EPS. The company’s revenue for the quarter was up 51.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.